Search Results - "Prenen, H."

Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma by Finisguerra, V, Prenen, H, Mazzone, M

“…A lot of attention has been dedicated to investigate the role of the tyrosine kinase receptor MET in tumors. The acquired notion that cancer cells from…”
Get full text

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis by De Smedt, L, Lemahieu, J, Palmans, S, Govaere, O, Tousseyn, T, Van Cutsem, E, Prenen, H, Tejpar, S, Spaepen, M, Matthijs, G, Decaestecker, C, Moles Lopez, X, Demetter, P, Salmon, I, Sagaert, X

“…Background: Microsatellite instability (MSI) accounts for 15% of all colorectal tumours. Several specific clinicopathologicals (e.g., preference for the…”
Get full text

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study by Van Cutsem, E., Boni, C., Tabernero, J., Massuti, B., Middleton, G., Dane, F., Reichardt, P., Pimentel, F.L., Cohn, A., Follana, P., Clemens, M., Zaniboni, A., Moiseyenko, V., Harrison, M., Richards, D.A., Prenen, H., Pernot, S., Ecstein-Fraisse, E., Hitier, S., Rougier, P.

“…Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II…”
Get full text

Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy by Delombaerde, D., Vervloet, D., Franssen, C., Croes, L., Gremonprez, F., Prenen, H., Peeters, M., Vulsteke, C.

“…Cardiovascular adverse events induced by immune checkpoint inhibitors (ICIs) have gained significant interest over the past decade due to their impact on…”
Get full text

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer by Macarulla, T, Cervantes, A, Tabernero, J, Roselló, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B, Jego, V, von Richter, O, Ciardiello, F

“…Background: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic…”
Get full text

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients by Van Cutsem, E., Prenen, H., D'Haens, G., Bennouna, J., Carrato, A., Ducreux, M., Bouché, O., Sobrero, A., Latini, L., Staines, H., Oum'Hamed, Z., Dressler, H., Studeny, M., Capdevila, J.

“…This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with…”
Get full text

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer by Van Cutsem, E., Machiels, J., Van den Eynde, M., Prenen, H., Hendlisz, A., Shaza, L., Carrasco, J., Canon, J., Sotiropoulou, P., Breman, E., Alcantar, E., Flament, A.

Get full text

Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic by Bennett, S, Søreide, K, Gholami, S, Pessaux, P, Teh, C, Segelov, E, Kennecke, H, Prenen, H, Myrehaug, S, Callegaro, D, Hallet, J

“…We aimed to review data about delaying strategies for the management of hepatobiliary cancers requiring surgery during the covid-19 pandemic. Given the…”
Get full text

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) by Piessevaux, H., Buyse, M., De Roock, W., Prenen, H., Schlichting, M., Van Cutsem, E., Tejpar, S.

“…Early radiological tumor shrinkage may be associated with better long-term outcome in chemorefractory metastatic colorectal cancer (cmCRC) treated with…”
Get full text

Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC) by Chiritescu, G., Dumon, K., Verslype, C., Prenen, H., Houbiers, G., Peeters, M., Janssens, J., Van Daele, D., Laurent, S., Arts, J., Hendrickx, K., Borbath, I., Ferrante, M., Bastin, F., Goeminne, J., Van Laethem, J., Vanderstraeten, E., Decaestecker, J., Van Vaerenbergh, W., Delhougne, B., Van Cutsem, E.

Get full text

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study by Gallois, C., Bergen, E.S., Auclin, É., Pernot, S., Higué, J., Trouilloud, I., Touchefeu, Y., Turpin, A., Mazard, T., Sartore-Bianchi, A., Prenen, H., Alberti, A., Pilla, L., Cuissy, S., Wookey, V., Perret, A., Melchior, C., Artru, P., Dubreuil, O., Drouillard, A., Doat, S., Lavolé, J., Basile, D., Perkins, G., Jary, M., Stintzing, S., Ros, J., Tougeron, D., Taieb, J.

“…The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) after a…”
Get full text

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future by Geukens, T., Brandão, M., Laenen, A., Collignon, J., Van Marcke, C., Louviaux, I., Demey, W., Van Wambeke, S., Schrijvers, D., Lecomte, S., Mebis, J., Rutten, A., Fontaine, C., Lybaert, W., Aspeslagh, S., Goeminne, J.-C., Van Den Bulck, H., Seront, E., De Backer, L., De Roock, W., Ignatiadis, M., Prenen, H., Van Beckhoven, D., Heijlen, M., Verheezen, J., Rottey, S., Punie, K., de Azambuja, E.

“…Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective…”
Get full text

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review by Schöffski, P., Dumez, H., Clement, P., Hoeben, A., Prenen, H., Wolter, P., Joniau, S., Roskams, T., Van Poppel, H.

“…Advanced and metastatic renal cell cancer (RCC) is resistant to conventional chemotherapy. Only a very small number of patients survive long term after…”
Get full text

The role of chemotherapy in biliary tract carcinoma by Verslype, C., Prenen, H., Van Cutsem, E.

“…Cholangiocarcinoma is a rare malignancy associated with poor prognosis and high mortality. Surgical resection is the only chance for cure depending on careful…”
Get full text

PD-0129: FDG-PET/CT for prediction and assessment of pathological response to induction CRT for esophageal carcinoma by Dirix, P, Deroose, C, Nafteux, P, Lerut, T, Coolen, J, De Hertogh, G, Prenen, H, Van Cutsem, E, Haustermans, J

Get full text

A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer by Van Cutsem, E, Prenen, H, Guillen-Ponce, C, Bennouna, J, Di Benedetto, M, Bouche, O, Staines, H, Oum'Hamed, Z, Studeny, M, Capdevila, J

Get full text

Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography–tandem mass spectrometry by Guetens, G., Prenen, H., De Boeck, G., Van Dongen, W., Esmans, E., Lemière, F., van Oosterom, A.T., Schöffski, P., de Bruijn, E.A.

“…The development of an on-column focusing gradient capillary LC method coupled to tandem mass spectrometry (quadrupole-linear ion trap) for the quantitative…”
Get full text

278MO Adherence optimisation, benefits, and limitations of oral anti-cancer therapy: A systematic review of patient preferences by Davies, A.G., Buckley, D., Raghunath, A., Martin, K., Prenen, H., Cook, O., Segelov, E.

Get full text

610P Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation by Seghers, S., Mando, P., Tan, C.J.L., Eid, M., Jayraj, A.S., Teuwen, L-A.M.N., Young, J., Segelov, E., Prenen, H.

Get full text

611P ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22) by Mando, P., Faisal, M.S., Jatwani, K., Seghers, S., Young, J., Teuwen, L-A.M.N., Prenen, H., Luong, T.T.V., Segelov, E.

Get full text